References
- Sherer TB, Betarbet R, Testa CM. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 2003;23:10756–10764.
- Aarsland D, Creese B, Politis M. Cognitive decline in Parkinson disease. Nat Rev Neurol 2017;13:217–231.
- Martinez-Martin P. The importance of non-motor disturbances to quality of life in Parkinson's disease. J Neurol Sci 2011;310:12–16.
- Kieburtz K, Wunderle KB. Parkinson's disease: evidence for environmental risk factors. Mov Disord 2013;28:8–13.
- Hwang O. Role of oxidative stress in Parkinson's disease. Exp Neurobiol 2013;22:11–17.
- Liu Y, Sun JD, Song LK, et al. Environment-contact administration of rotenone: a new rodent model of Parkinson's disease. Behav Brain Res 2015;294:149–161.
- Coulom H, Birman S. Chronic exposure to rotenone models sporadic Parkinson's disease in Drosophila melanogaster. J Neurosci 2004;24:10993–10998.
- Bretaud S, Lee S, Guo S. Sensitivity of zebrafish to environmental toxins implicated in Parkinson's disease. Neurotoxicol Teratol 2004;26:857–864.
- Wang Y, Liu W, Yang J, et al. Parkinson's disease-like motor and non-motor symptoms in rotenone-treated zebrafish. Neurotoxicology 2017;58:103–109.
- Khotimah H, Ali M, Sumitro SB, et al. Decreasing α-synuclein aggregation by methanolic extract of Centella asiatica in zebrafish Parkinson's model. Asian Pac J Trop Biomed 2015;5:948–954.
- Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265–275.
- Yagi K. Assay for blood plasma or serum. Methods Enzymol 1981;105:328–337.
- Miranda KM, Espey MG, Wink DA. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001;5:62–71.
- Mylroie AA, Collins H, Umbles C, et al. Erythrocyte superoxide dismutase activity and other parameters of copper status in rats ingesting lead acetate. Toxicol Appl Pharmacol 1986;82:512–520.
- Oktay S, Alev-Tu¨zu¨ner B, Tunalı S, et al. Investigation of the effects of edaravone on valproic acid induced tissue damage in pancreas. Marmara Pharm J 2017;3:570–577.
- Habig WH, Jakoby WB. Assays for differentiation of glutathione S-transferases. Meth Enzymol 1981;77:398–405.
- Aebi H. Catalase in vitro. Meth Enzymol 1984;105:121–126.
- Khatri DK, Juvekar AR. Abrogation of locomotor impairment in a rotenone-induced Drosophila melanogaster and zebrafish model of Parkinson’s disease by ellagic acid and curcumin. Int J Nutr Pharmacol Neurol Dis 2016;6:90–96.
- Houser MC, Tansey MG. The gut-brain axis: is intestinal inflammation a silent driver of Parkinson's disease pathogenesis? NPJ Parkinsons Dis 2017;3:3.
- Tarozzi A, Angeloni C, Malaguti M, et al. Sulforaphane as a potential protective phytochemical against neurodegenerative diseases. Oxid Med Cell Longev 2013;2013:1.
- Greenamyre JT, Betarbet R, Sherer TB. The rotenone model of Parkinson's disease: genes, environment and mitochondria. Parkinsonism Relat Disord 2003;9:59–S64.
- Kuo YM, Li Z, Jiao Y, et al. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum Mol Genet 2010;19:1633–1650.
- Pan-Montojo F, Schwarz M, Winkler C, et al. Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep 2012;2:898.
- Angelova PR, Horrocks MH, Klenerman D, et al. Lipid peroxidation is essential for α-synuclein-induced cell death. J Neurochem 2015;133:582–589.
- Stone DK, Kiyota T, Mosley RL, et al. A model of nitric oxide induced α-synuclein misfolding in Parkinson’s disease. Neurosci Lett 2012;523:167–173.